tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Promising Advancements and Strategic Positioning Drive Buy Rating for Entrada Therapeutics Inc.
PremiumRatingsPromising Advancements and Strategic Positioning Drive Buy Rating for Entrada Therapeutics Inc.
2M ago
Entrada Therapeutics files $400M mixed securities shelf
Premium
The Fly
Entrada Therapeutics files $400M mixed securities shelf
2M ago
Entrada Therapeutics reports Q3 EPS ($1.06), consensus (96c)
Premium
The Fly
Entrada Therapeutics reports Q3 EPS ($1.06), consensus (96c)
2M ago
Buy Rating for Entrada Therapeutics: Strong Pipeline and Financial Stability Amidst DMD Advancements
PremiumRatingsBuy Rating for Entrada Therapeutics: Strong Pipeline and Financial Stability Amidst DMD Advancements
5M ago
Entrada Therapeutics Reports Q2 2025 Financial Results
Premium
Company Announcements
Entrada Therapeutics Reports Q2 2025 Financial Results
5M ago
Promising Clinical Developments and Strategic Pipeline Expansion Support Buy Rating for Entrada Therapeutics
Premium
Ratings
Promising Clinical Developments and Strategic Pipeline Expansion Support Buy Rating for Entrada Therapeutics
5M ago
Buy Rating for Entrada Therapeutics: Strategic Positioning and Regulatory Advances in Exon-Skipping Therapeutics
PremiumRatingsBuy Rating for Entrada Therapeutics: Strategic Positioning and Regulatory Advances in Exon-Skipping Therapeutics
7M ago
Entrada Therapeutics receives authorization from in EU to start ELEVATE-45-201
Premium
The Fly
Entrada Therapeutics receives authorization from in EU to start ELEVATE-45-201
8M ago
Entrada Therapeutics price target lowered to $21 from $23 at Roth Capital
Premium
The Fly
Entrada Therapeutics price target lowered to $21 from $23 at Roth Capital
8M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100